STOCKWATCH
·
Biotechnology: Commercial Physical & Biological Resarch
Corporate GovernanceApr 29, 2026, 07:07 AM

ICLR: Non-Reliance on Past Financials; Revenue Overstated

AI Summary

ICON plc's Audit Committee has concluded that previously issued financial statements for 2023, 2024, and interim periods from Q1 2023 to Q3 2025 should no longer be relied upon. An investigation found revenue was overstated in 2023 and 2024, with a lesser impact in 2025. The company plans to restate these financials in its upcoming 2025 Annual Report on Form 20-F, which will also detail identified material weaknesses and remediation plans.

Key Highlights

  • Audit Committee concluded non-reliance on previously issued financial statements.
  • Affected periods include audited 2023, 2024, and unaudited Q1 2023 to Q3 2025.
  • Investigation found revenue overstated in 2023 and 2024, below 2% upper limit.
  • Similar, but lesser, revenue overstatement issues identified in 2025.
  • Company intends to restate financials in its 2025 Annual Report on Form 20-F.
  • The 2025 Annual Report will detail material weaknesses and remediation plans.
ICLR
Biotechnology: Commercial Physical & Biological Resarch
ICON PLC

Price Impact